Plasmakoncentrationerne af nelfinavir, som fortrinsvis metaboliseres af CYP2C19 og kun delvis af CYP3A4, øges kun lidt ved samtidig administration af ritonavir, derfor synes samtidig administration af nelfinavir med lavdosis ritonavir ikke at være fordelagtigt.
Plasma levels of nelfinavir, which is metabolised predominantly by CYP2C19 and only partially by CYP3A4, are not greatly increased by co-administration with ritonavir, and therefore co-administration of nelfinavir with low-dose ritonavir does not appear to be beneficial.